AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03759028
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
Trial: NCT02194777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02842125
Drug: Ad-P53
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
Trial: NCT02810483
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ncrease phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days.
Trial: NCT00082706
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
Trial: NCT01325818
Drug: pravastatin, rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day~2. Active Comparator Intervention: Drug: rosuvastatin 20mg/day
Trial: NCT00427297
Drug: ABC/3TC/NVP (abacavir/lamivudine/nevirapine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line regimen
Trial: NCT03336073
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15
Trial: NCT00585208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo for ramelteon 8mg daily
Trial: NCT04045522
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Based on routine treatment, 4 mg zoledronic acid (Novartis Pharma Stein AG, Switzerland, registration No. H20140218) was intravenously administered, once every 3-4 weeks, for 1-2 years.
Trial: NCT02216149
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
Trial: NCT01562483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical to the Namisol arm.
Trial: NCT02768077
Drug: Melatonin(Circadin®)
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02768077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01329185
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule twice a day for 14 days prior to transplant date
Trial: NCT03007693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ- 61393215 matching placebo for 7 days.
Trial: NCT04214691
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
Trial: NCT00549042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04043806
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) tablet for oral administration.
Trial: NCT04679597
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparison of two treatments
Trial: NCT02611921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
Trial: NCT03069014
Drug: 400mg LM11A-31-BHS
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 Oral Capsules (200mg of LM11A-31-BHS and 200mg of placebo) twice daily (morning \& evening) for 26 weeks
Trial: NCT03069014
Drug: 800mg LM11A-31-BHS
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 Oral Capsules (200mg of LM11A-31-BHS) twice daily (morning \& evening) for 26 weeks
Trial: NCT03069014
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Oral Capsules (200mg of Placebo) twice daily (morning \& evening) for 26 weeks
Trial: NCT00621946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Matching Escitalopram
Trial: NCT00721825
Drug: Neuroaid matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroaid matched placebo 4 capsules three times per day during one month
Trial: NCT02021292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral tablet, to be taken once daily.
Trial: NCT04501978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion
Trial: NCT02788045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.
Trial: NCT01229527
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
Trial: NCT01229527
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
Trial: NCT03955445
Drug: LNP023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNP023 capsules
Trial: NCT02828592
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14.5 mg/kg/day IV x 2 doses (Days -6 \& -5)
Trial: NCT02828592
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Post-transplant: 50 mg/kg IV QD (Day +3 to +4)
Trial: NCT04167085
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline, 100 mg twice a day for 2 months
Trial: NCT03036124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching dapagliflozin 10 mg or 5 mg.
Trial: NCT01283971
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 10-25 mg weekly.
Trial: NCT00584376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
Trial: NCT01766323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
Trial: NCT02177435
Drug: Telmisartan/Hydrochlorothiazide
RxNorm normalized name: telmisartan/hydrochlorothiazide 80 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02177435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01038674
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
Trial: NCT03044093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The group that will only get Misoprostol
Trial: NCT04551703
Drug: Adrenaline saline irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The surgical field is flushed with 20 cc of Adrenaline saline irrigation. This is in contrast to the standard of care, normal saline irrigation.
Trial: NCT00432575
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT02722122
Drug: AIR DNase™
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00730210
Drug: a: PTH (1-84)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preotact 100 microgram subcutaneous a day in 6 months
Trial: NCT00730210
Drug: b:placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microgram placebo subcutaneous a day for 6 months
Trial: NCT02979613
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tablet administered orally once daily
Trial: NCT02979613
Drug: TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT02979613
Drug: TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT03303625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
Trial: NCT01613807
Drug: Insulin, Long-Acting and Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual insulin regimen: Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
Trial: NCT00672763
Drug: Colecalciferol D3 (Vigantol Oil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses).
Trial: NCT00672763
Drug: Medium chain triglycerides
RxNorm normalized name: medium chain triglycerides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Migliol Oil 5ml oral fortnightly (2 doses)
Trial: NCT01136746
Drug: Human regular insulin
RxNorm normalized name: Human regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
Trial: NCT02596399
Drug: DSTA4637S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive DSTA4637S intravenously on Day 1.
Trial: NCT02596399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
Trial: NCT02515656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00518583
Drug: Pegylated Liposomal Doxorubicin (Doxil)
RxNorm normalized name: doxorubicin hydrochloride liposome Injection [Doxil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly
Trial: NCT02422641
Drug: High-dose Methotrexate (8 gm/m2; HD-MTX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (\~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
Trial: NCT02435797
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
Trial: NCT02603861
Drug: LY3154207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3154207 administered orally.
Trial: NCT02603861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally.
Trial: NCT01543906
Drug: QLT091001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral QLT091001 administered once daily for 7 days
Trial: NCT00405912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inactive drug) given 3 times per day
Trial: NCT01965145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile solution administered subcutaneously
Trial: NCT04491006
Drug: ATH-1017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe
Trial: NCT04491006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe
Trial: NCT00598286
Drug: [18F]FMPEP-d2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04838145
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to treatment with placebo
Trial: NCT02503306
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablets Route of administration: oral
Trial: NCT04230252
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.
Trial: NCT03564379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet will be administered orally.
Trial: NCT02986659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00571558
Drug: aminolevulinic acid hydrochloride
RxNorm normalized name: Aminolevulinic Acid Hydrochloride
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00571558
Drug: photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo photodynamic therapy
Trial: NCT01107106
Drug: ellaOne® (ulipristal acetate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one single oral dose (30 mg tablet)
Trial: NCT00540384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00733577
Drug: SB756050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
Trial: NCT00132951
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telithromycin (AECB: 2 tablets per day for Days 1-5; CAP: 2 tablets per day for Days 1-7)
Trial: NCT00132951
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AECB: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5; CAP: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5 then 2 placebo tablets per day for Days 6-7)
Trial: NCT00447629
Drug: PPM-204
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00978497
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral BID
Trial: NCT00978497
Drug: ANA598
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral 400mg BID
Trial: NCT00000578
Drug: theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01093170
Drug: RNA-144101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreous administration of RNA-144101
Trial: NCT02512861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients \> 50 kgs
Trial: NCT04335591
Drug: Placebo capsule to match Add-back capsule
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral administration once daily
Trial: NCT03498131
Drug: 3 mg Melatonin
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 mg melatonin once each day
Trial: NCT03498131
Drug: 5 mg Melatonin
RxNorm normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg Melatonin once each day
Trial: NCT03730311
Drug: Elpida
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elsulfavirine, capsules
Trial: NCT03730311
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04394234
Drug: Direct oral anticoagulant (DOACs)
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data of participants newly exposed to individual DOACs that is rivaroxaban, apixaban, dabigatran from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
Trial: NCT00922441
Drug: Reference (Valsartan 80 mg) group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference (Valsartan 80 mg)
Trial: NCT01887990
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline infusion
Trial: NCT03248713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sugar 2 tablets will be compared to mifepristone
Trial: NCT01359878
Drug: Isotonic Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline in equivalent volume - 100 ml
Trial: NCT02188277
Drug: Botox®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
Trial: NCT02242799
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
Trial: NCT02798913
Drug: Long DAPT
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
Trial: NCT03405441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive matching placebo orally in Part 1 and Part 2 of the study.
Trial: NCT03690921
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01525641
Drug: Mirapex LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole Hydrochloride Hydrate
Trial: NCT00735462
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied daily to wart areas for up to 8 weeks
Trial: NCT02236598
Drug: K+ supplement
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02236598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03220165
Drug: MGL-3196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, 100 mg
Trial: NCT00945763
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT04097691
Drug: GLUCOSE 10%
RxNorm normalized name: glucose 10% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous glucose 0.5 ml per site around subcutaneous nerves
Trial: NCT04853407
Drug: LY03005 extended-release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally once a day
Trial: NCT04853407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally once a day
Trial: NCT00510263
Drug: Prednisolone + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
Trial: NCT00510263
Drug: Placebo + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
Trial: NCT00993018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive single injection of matching placebo every 28 days for up to 52 weeks.